Primary Site >> Pancreatic Cancer

Gene >> MST1R

  • 2004
  • 2006
  • 2007
  • 2008
  • 2009
  • 2010
  • 2011
  • 2012
  • 2014
  • 2016
  • 2017
  • 2018
Ref: Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression.
PMID: 15289319
Ref: Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
PMID: 16982759
Ref: Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target.
PMID: 17311308
Ref: Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells.
PMID: 18310076
Ref: In memoriam: Great 21st century physician 'One Health' leader dies - Ronald M. Davis, MD, Past President, American Medical Association.
PMID: 20391399
Ref: Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.
PMID: 20103639
Ref: The RON tyrosine kinase receptor regulates vascular endothelial growth factor production in pancreatic cancer cells.
PMID: 20358644
Ref: Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
PMID: 20428780
Ref: Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.
PMID: 20694025
Ref: IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration.
PMID: 21565828
Ref: Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein.
PMID: 21619683
Ref: Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.
PMID: 22014215
Ref: Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitors.
PMID: 22287729
Ref: RON is not a prognostic marker for resectable pancreatic cancer.
PMID: 22958871
Ref: Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells.
PMID: 24233399
Ref: The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.
PMID: 24518495
Ref: A novel protein isoform of the RON tyrosine kinase receptor transforms human pancreatic duct epithelial cells.
PMID: 26477314
Ref: Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.
PMID: 27293990
Ref: Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.
PMID: 27314431
Ref: A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts.
PMID: 27602776
Ref: Identification of candidate genes related to pancreatic cancer based on analysis of gene co-expression and protein-protein interaction network.
PMID: 29050346
Ref: Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
PMID: 29944378